Century Therapeutics Reports Q2 2025 Financials and Updates

Century Therapeutics, Inc. ( (IPSC) ) has released its Q2 earnings. Here is a breakdown of the information Century Therapeutics, Inc. presented to its investors.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer. The company leverages its expertise in cellular reprogramming and genetic engineering to create off-the-shelf cell therapies aimed at improving patient access and treatment outcomes.

In its second quarter 2025 financial results, Century Therapeutics reported ongoing patient dosing in the CALiPSO-1 trial and progress in its CNTY-308 program. The company also announced the appointment of Dr. Brent Pfeiffenberger as Board Chair, extending its cash runway into the fourth quarter of 2027.

Key highlights include the continued enrollment in the CALiPSO-1 trial for CNTY-101, with clinical data expected by the end of 2025. The CNTY-308 program is advancing through IND-enabling studies, with clinical trials anticipated in 2026. Additionally, Century has made strides in its non-immune cell program, showcasing its Allo-Evasion™ 5.0 technology.

Financially, the company reported a net loss of $32.5 million for the quarter, with cash and marketable securities totaling $158.5 million as of June 30, 2025. Research and development expenses saw a slight decrease, while general and administrative expenses also declined compared to the previous year.

Looking ahead, Century Therapeutics remains focused on advancing its pipeline and delivering clinical data for CNTY-101. The company aims to continue its strategic development efforts, leveraging its innovative technologies to bring transformative therapies to patients with autoimmune diseases and cancer.